$10 Billion Deal, page-3071

I am sorry, but which part of this suggests that the current lead compound is 'shelved'? Is Dav misleading the market with his bull poo character assassination of PN and MM again. Can the lad read?

As highlighted in the presentation:

 The completed Phase 2 HIV-1 clinical trial demonstrated that Biotron’s lead compound, BIT225,demonstrated significant, potentially beneficial immunological changes, not seen in patients only receiving current antiretroviral treatment.

 The results point to a potential role for BIT225 in improving patient health outcomes, as well as in future HIV-1 eradication strategies.

 The results support the ongoing clinical development of thisimportant new class of anti-HIV drug.

 Additional analyses of patient samples from the Phase 2 HIV-1 trial are ongoing, to further characterise the observed immunological changes seen in the trial.

 Biotron’s Hepatitis B virus (HBV) program is progressing well, with compounds reducing levels of HBVcccDNA, which is believed to be critical for eradication of this virus. Current treatments suppress virus replication but do not offer a cure.

Biotron’s Viroporin-targeting platform is an important tool in the development of a newclass of direct-acting antiviral therapies with the additional potential to impact on immune activation linked to viral pathogenesis

This from the recent BIO 2019 in Philly.